DBV Technologies | DBVT - Operating Profit


DBV Technologies reported $-34.28M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Acadia Pharmaceuticals USD 35.76M 3.38M Sep/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Amarin USD -1.7M 8.47M Sep/2025
BioCryst Pharmaceuticals USD -2.54M 10.23M Dec/2024
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
DBV Technologies USD -34.28M 6.83M Sep/2025
Esperion Therapeutics USD -16.03M 18.6M Sep/2024
Galectin Therapeutics USD -11.29M 1.64M Jun/2024
Halozyme Therapeutics USD -88.41M 306.33M Dec/2025
Incyte USD 383.88M 47.43M Dec/2025
Insmed USD -249.71M 11.64M Dec/2025
Ionis Pharmaceuticals USD -160.18M 300.02M Sep/2025
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
PTC Therapeutics USD -81.62M 85.11M Dec/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
United Therapeutics USD 389.3M 112.4M Sep/2025